Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Three types of subject:~Neonates whose mothers are positive for both HBsAg and HBeAg~Neonates whose mothers are positive for only HBsAg~Neonates whose mothers are negative for both HBsAg and HBeAg~INCLUSION CRITERIA:~* Full-term neonates with gestational age from 37 weeks to 42 weeks;~* Apgar scores are no less than 7 at birth;~* Neonates with standard body temperature (auxiliary temperature \< 37.1°);~* Neonates weighing ≥ 2,500 grams at birth;~* Neonates with icteric index within the normal range (physiologic jaundice is permitted);~* Informed consent form signed by parent/guardian;~* The requirements of the clinical trial protocol can be observed on the basis of the opinion of the investigator.~EXCLUSION CRITERIA:~* Subject's parent has a history of family diseases such as convulsion and brain diseases;~* Mothers have low immunologic function or a history of organ transplantation or hemodialysis;~* Subject's parent is allergic to any composition of Hepatitis B vaccine;~* A family history of thrombocytopenia, or other disturbance of blood coagulation, which may result in a contraindication for intramuscular injection;~* Known immunologic function damage;~* Mothers had received gamma globulin or immunoglobulin injection during pregnancy;~* Any congenital malformation~* Known or suspected to suffer from diseases such as active infection and cardiovascular disease;~* Any condition believed by the investigator to have possible impact on trial evaluation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Day
- Healthy Volunteers: t

Study Arms:
- HepavaxGene Stratum 1a (Type: EXPERIMENTAL): Subjects of mothers with chronic hepatitis B (positive for both HBsAg and hepatitis B envelope antigen - HBeAg)
- Comparator vaccine Stratum 1a (Type: ACTIVE_COMPARATOR): Subjects of mothers with chronic hepatitis B (positive for both HBsAg and HBeAg)
- HepavaxGene Stratum 1b (Type: EXPERIMENTAL): Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
- Comparator vaccine Stratum 1b (Type: ACTIVE_COMPARATOR): Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
- HepavaxGene Stratum 2 (Type: EXPERIMENTAL): Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
- Comparator vaccine Stratum 2 (Type: ACTIVE_COMPARATOR): Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)

Based on this trial design, predict the completion outcome and termination type (if applicable).